Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.

Autor: Fletcher CE; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Sulpice E; Université Grenoble Alpes, CEA, INSERM, BIG, BGE, 17 Avenue des Martyrs, 38054, Grenoble, France., Combe S; Université Grenoble Alpes, CEA, INSERM, BIG, BGE, 17 Avenue des Martyrs, 38054, Grenoble, France., Shibakawa A; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Leach DA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Hamilton MP; Department of Molecular and Cellular Biology, Baylor College of Medicine, 1 Baylor Plaza Houston M822, Houston, TX, 77030, USA., Chrysostomou SL; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Sharp A; Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Welti J; Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Yuan W; Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., Dart DA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK., Knight E; Tumour Profiling Unit, Institute of Cancer Research, London, SW3 6JB, UK., Ning J; Tumour Profiling Unit, Institute of Cancer Research, London, SW3 6JB, UK., Francis JC; Tumour Profiling Unit, Institute of Cancer Research, London, SW3 6JB, UK., Kounatidou EE; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Gaughan L; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Swain A; Tumour Profiling Unit, Institute of Cancer Research, London, SW3 6JB, UK., Lupold SE; The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., de Bono JS; Prostate Cancer Target Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK., McGuire SE; Department of Molecular and Cell Biology, Baylor College of Medicine Hospital, Houston, TX, USA.; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gidrol X; Université Grenoble Alpes, CEA, INSERM, BIG, BGE, 17 Avenue des Martyrs, 38054, Grenoble, France., Bevan CL; Imperial Centre for Translational and Experimental Medicine, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. charlotte.bevan@imperial.ac.uk.

Publikováno v: Oncogene [Oncogene] 2019 Jul; Vol. 38 (28), pp. 5700-5724. Date of Electronic Publication: 2019 May 01.

The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Autor: Hepburn AC; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. anastasia.hepburn@newcastle.ac.uk., Steele RE; Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer, Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, BT9 7AE, UK., Veeratterapillay R; Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK., Wilson L; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Kounatidou EE; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Barnard A; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Berry P; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Cassidy JR; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Moad M; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., El-Sherif A; Department of Pathology, Royal Victoria Infirmary, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK., Gaughan L; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK., Mills IG; Prostate Cancer UK/Movember Centre of Excellence for Prostate Cancer, Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, BT9 7AE, UK.; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 9DU, UK., Robson CN; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. c.n.robson@newcastle.ac.uk., Heer R; Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. rakesh.heer@newcastle.ac.uk.; Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK. rakesh.heer@newcastle.ac.uk.

Publikováno v: Oncogene [Oncogene] 2019 May; Vol. 38 (22), pp. 4412-4424. Date of Electronic Publication: 2019 Feb 11.